Evidence map›Paper›PMID 26457110›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2015

Compound Danshen Dripping Pill for Treating Early Diabetic Retinopathy: A Randomized, Double-Dummy, Double-Blind Study.

Dan Luo, Yali Qin, Wei Yuan, Hui Deng, Youhua Zhang, Ming Jin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Dan LuoDepartment of Graduate School, Beijing University of Chinese Medicine, No. 11, North 3rd Ring East Road, Chaoyang District, Beijing 100029, China ; Department of Ophthalmology, China-Japan Friendship Hospital, Yinghua Donglu, Chaoyang District, Beijing 100029, China.
Yali QinDepartment of Graduate School, Beijing University of Chinese Medicine, No. 11, North 3rd Ring East Road, Chaoyang District, Beijing 100029, China ; Department of Ophthalmology, China-Japan Friendship Hospital, Yinghua Donglu, Chaoyang District, Beijing 100029, China.
Wei YuanDepartment of Ophthalmology, China-Japan Friendship Hospital, Yinghua Donglu, Chaoyang District, Beijing 100029, China.
Hui DengDepartment of Ophthalmology, China-Japan Friendship Hospital, Yinghua Donglu, Chaoyang District, Beijing 100029, China.
Youhua ZhangDepartment of Ophthalmology, China-Japan Friendship Hospital, Yinghua Donglu, Chaoyang District, Beijing 100029, China.
Ming JinDepartment of Ophthalmology, China-Japan Friendship Hospital, Yinghua Donglu, Chaoyang District, Beijing 100029, China.
China-Japan Friendship Hospital · CNBeijing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This randomized, double-dummy, double-blind study was to observe the therapeutic effects of compound Danshen dripping pill (CDDP) in treating early diabetic retinopathy (DR). All the 57 type 2 diabetes cases in nonproliferative diabetic retinopathy (NPDR) stage were divided into two groups randomly: 28 cases treated with CDDP as the treated group and 29 cases treated with calcium dobesilate as the control group. The best corrected visual acuity (BCVA) in the treated group was significantly improved after treatment when compared to that before treatment (P < 0.05). Mean defect (MD) of visual field, hemorrhage area of the fundus, microaneurysm number, fluorescent leakage area, and capillary nonperfusion area evaluated by visual field, fundus photography, and fundus fluorescein angiography in the treated group had the same results as BCVA. However, there was no statistical difference in each index between the two groups. No obvious adverse events with clinical significance occurred. Our present study showed that CDDP has a similar improvement and safety to calcium dobesilate for NPDR. In future DR treatments, CDDP may function as the auxiliary drug.

Identifiers

PMID26457110
PMCPMC4592726
OpenAlexW1932129717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.